跳至主要内容
临床试验/NCT03714451
NCT03714451已完成不适用

Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes

Yale University6 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
6
主要终点
Change in glycemic variability

研究概览

简要总结

To evaluate the effect of onyx sorghum on blood glucose levels in patients with type 2 diabetes (T2DM).

详细描述

The plan is to study 24 participants with T2DM, who are otherwise healthy. The study will be double-blinded and randomized. Participants will first attend a screening visit (Visit #1) to determine eligibility. Then, eligible participants will be asked to wear a FreeStyle Libre Pro continuous glucose monitor (CGM) for up to 14 days (Visit #2). After this 14-day CGM session, participants will be randomly assigned (1:1) to one of two groups that will receive: 1) food products containing onyx sorghum (Onyx Group) or 2) food products with wheat flour (Control Group). The diet intervention will last a total of 28 days. Participants will have weekly visits to pick up food and bi-weekly blood draws (no more than 20mL at each visit). They will also be asked to wear the CGM throughout the diet intervention and will record their food intake in a daily food diary to confirm that the diet intervention is being followed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

double blinded

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 30-65 years
  • A1c < 8.5%
  • BMI > 18.5

排除标准

  • known malignancy, anemia, kidney disease, and/or liver disease
  • untreated thyroid disease
  • uncontrolled hypertension
  • initiation of any anti-diabetes medications within the last 3 months
  • greater than 5% change in weight in the last 3 months
  • current or recent steroid use in the last 3 months
  • for women: pregnancy or breastfeeding

结局指标

主要结局

Change in glycemic variability

时间窗: day 28

The continuous glucose monitoring (CGM) consists of a sensor that measures glucose levels from the interstitial tissue. Changes in glucose levels from baseline.

次要结局

  • Changes in BMI(day 28)
  • Changes in weight(day 28)
  • Change in glucose levels(day 28)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验